Clinical Trial Update: Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets) [Phase 1]

View source ↗

Summary

A Phase 1 trial of cinacalcet for FGF23-mediated hypophosphatemia causing hypophosphatemic rickets has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypophosphatemic Rickets
• Osteomalacia

Drugs mentioned

• cinacalcet (cinacalcet hydrochloride)

Snippet

Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) | Conditions: Osteomalacia | Phase 1 | Status: TERMINATED